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Reply to: “Brief Clinical Rating
Scales Should Not Be
Overlooked”
We thank Professor Lim and colleagues for commending
the Progressive Supranuclear Palsy-Clinical Deficits Scale
(PSP-CDS)1 in their letter, “Brief clinical rating scales should
not be overlooked.”2 The PSP-CDS is a physician-rated scale
that was recently developed by members of the Movement
Disorder Society (MDS)-endorsed PSP study group to reliably
assess disease severity and progression in patients with PSP,
regardless of the clinical phenotype.1
The full version of the scale (PSP-CDS7x3) comprises seven
items with three response categories each (0 = no deficit;
1 = mild deficits not affecting activities of daily living (ADL);
2 = moderate deficits requiring partial external support;
3 = severe deficits necessitating permanent external support).
The abbreviated PSP-CDS7x2 scale omits the response cate-
gory for mild clinical deficits, to be used in research settings,
where such items without ADL-impact are of minor impor-
tance (eg, pivotal clinical trials). Finally, the short PSP-CDS6x2
scale omits the item “Eye movements” from PSP-CDS7x2
because their importance for ADL is controversial.
As a measure of clinical meaningful deficits that generates
scores with appropriate annual sensitivity to change and a
completion time of ~4 minutes,1 we suggest the PSP-CDS be
applied in the context of clinical trials and in clinical routine
care to monitor disease progression and to identify clinical
deficits requiring medical attention.
We would like to point out, however, that we do not consider
the PSP-CDS as a substitute for the Progressive Supranuclear Palsy
Rating Scale (PSPRS)3 in every instance, but rather a complemen-
tary instrument. The PSPRS is a 28-item scale to assess disease
severity and progression in PSP. The PSPRS proved to be a reliable
measure inmany PSP randomized controlled trials and observation
studies, as well as in routine clinical settings.4–6 Compared to the
PSP-CDS, the PSPRS assesses a larger number of items and has
slightly better sensitivity to change but is less established for PSP
with variant phenotypes (other than Richardson’s syndrome) and
takes more than three times as long to be completed.3 This trade-
off needs to be considered based on the situation.
Prof. Lim and colleagues point out that the inability of
severely disabled patients to complete comprehensive exami-
nations, unavailability of personnel, and time constraints are
potentially creating barriers for the use of lengthy scales in
clinical routine and a bias in research applications.2 Hence, in
such situations, shorter scales, such as the PSP-CDS or the
Clinical Impression of Severity Index for Parkinson’s Disease
(CISI-PD)7 as mentioned by Lim and colleagues,2 bear signifi-
cant advantages. Further validation of the PSP-CDS will facili-
tate the decision on when to use the PSPRS or the PSP-CDS.
Translation of the PSP-CDS into other languages is underway
and will allow application in diverse geographical locations.
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Analysis of four scales for global severity evaluation in Parkinson’s




We read with interest the study by Choe and colleagues1
who increases emphasis on the heart–brain axis in Parkinson’s
disease (PD). They have studied the relation between
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subclinical cardiac markers and motor impairment (Unified
Parkinson’s Disease Rating Scale Part III and Hoehn and
Yahr stage) and cognition (Montreal Cognitive Assessment
[MoCA]) concluding that (1) patients with PD presented
higher levels of N-terminal pro-B-type natriuretic peptide
(NT-proBNP) compared with healthy controls matched for
age, sex, and cardiovascular risk factors; (2) increased levels
of NT-proBNP and high-sensitivity troponin I were associated
with worse motor impairment (Unified Parkinson’s Disease
Rating Scale Part III and Hoehn and Yahr stage); and
(3) MoCA was inversely associated to high-sensitivity tropo-
nin I and NT-proBNP levels only in unadjusted models
among patients with PD.1 The population included were
patients with advanced-stage PD (12 years of disease duration
in average).1
We have replicated these analyses in an independent popula-
tion of patients with earlier stage PD (age 66 ± 9 years old, 56%
male, disease duration 4.2 ± 2.62 years, Unified Parkinson’s Dis-
ease Rating Scale Part III 24.5 ± 9.31) being evaluated for car-
diovascular risk factors. We conducted a case-control study
comparing patients with PD with non-PD controls. Patients with
PD were recruited sequentially from the Movement Disorders
Unit of the University Hospital of Santa Maria-Lisbon, and con-
trols were recruited from 1 general practitioner list from a pri-
mary healthcare center in the same geographic region. All
patients were diagnosed with PD by a movement disorders spe-
cialist according to the UK PD Brain Bank criteria2 and had
<11 years of disease duration. Controls were randomly selected
from a general practitioner’s list of patients and matched to the
patients with PD according to age and gender. All participants
were evaluated by an internal medicine physician and movement
disorders expert. Blood samples were taken and the MoCA test
was performed by a trained nurse. Dysautonomy/orthostatic
hypotension was defined as the decline of at least 20 mmHg in
systolic blood pressure and/or 10 mmHg in diastolic blood pres-
sure within 5 minutes of going from supine to standing. Partici-
pants with heart failure were excluded.
All comparisons between patients with PD and matched
controls did not reach significance (Table 1). In our analysis
of the NT-proBNP marker among patients with PD, we only
found higher significant results when comparing patients with
PD with and without orthostatic hypotension (254 ng/L vs.
135 ng/L; P = 0.028). We also did not find a significant asso-
ciation of NT-proBNP with motor impairment or MoCA test
in patients with PD.
Although our results are not conclusive, they go in the
same direction of the conclusions of Choe and colleagues.
The purpose of this letter is to add to the discussion the
possibility that this association between subclinical cardiac
markers and PD should be explored even at an earlier stage
of the disease.
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TABLE 1. Comparison between patients with PD and age-matched and gender-matched controls
Outcome PD, n = 100 Control, n = 100 P Value
NT-proBNP, mean ± SD (minimum; maximum) 158 ± 214 ng/mL (5; 1141) 143 ± 272 ng/mL (14; 1941) 0.65
NT-proBNP > 125 ng/L 32% 24% 0.21
NT-proBNP < 27 ng/L 9% 11% 0.64
MoCA, mean ± SD 22.0 ± 4.4 21.8 ± 5.3 0.85
NT-proBNP
Without OH 135.3 ± 177.6 ng/mL (n = 81)* 135.3 ± 252.6 ng/mL (n = 89)** —
With OH 254.3 ± 315.2 ng/mL (n = 19)* 73.40 ± 44.4 ng/mL (n = 10)** —
PD, Parkinson’s disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation; MoCA, Montreal Cognitive Assessment; OH, orthostatic
hypotension.
*P value = 0.028.
**P value = 0.44.
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